US 10314924
RPGR gene therapy for retinitis pigmentosa
granted A61KA61K48/005A61K9/0048
Quick answer
US patent 10314924 (RPGR gene therapy for retinitis pigmentosa) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K48/005, A61K9/0048, A61P, A61P27/02